Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Depreciation & Amortization (CF) (2020 - 2025)

HCW Biologics (HCWB) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $173905.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) rose 35.39% year-over-year to $173905.0, compared with a TTM value of $1.6 million through Sep 2025, up 101.86%, and an annual FY2024 reading of $1.2 million, up 4.33% over the prior year.
  • Depreciation & Amortization (CF) was $173905.0 for Q3 2025 at HCW Biologics, down from $291916.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $682507.0 in Q4 2024 and bottomed at $107463.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $235045.1, with a median of $173905.0 recorded in 2025.
  • Peak annual rise in Depreciation & Amortization (CF) hit 148.59% in 2024, while the deepest fall reached 54.3% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $107463.0 in 2021, then skyrocketed by 143.02% to $261158.0 in 2022, then grew by 5.13% to $274550.0 in 2023, then surged by 148.59% to $682507.0 in 2024, then crashed by 74.52% to $173905.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for HCWB at $173905.0 in Q3 2025, $291916.0 in Q2 2025, and $419010.0 in Q1 2025.